Antihypertensives in oral submucous fibrosis
Keywords:
anti hypertensives, Tobacco, OSMFAbstract
Oral submucous fibrosis is a common pre-malignant condition affecting the oral mucosa with more prevalence among Indian population. Various treatment modalities have been elucidated in order to alleviate the symptoms associated with OSMF. Currently oral Anti-hypertensive has been proved to have beneficial result in treating OSMF because of its anti-inflammatory, fibrinolytic, immunomodulatory and rheologic modifying property. Several categories of drugs have been used in the treatment of OSMF but their effectiveness leaves much to be desired and no treatment regimen has afforded definitive cure. While Oral administration limits the concentration of drugs in lesional tissue and increases the potential for side effects, the Intralesional injections are associated with significant mechanical injury and noncompliance on the patient’s part because of the accompanying discomfort and pain. The present study was done to evaluate the effectiveness of oral antihypertensives in the management of OSMF. Very few studies across world have showed that anti-hypertensive drugs showed significant improvement in mouth opening, reduction in burning sensation. Hence anti-hypertensive can be a good alternative in the management of OSMF for whom intralesional steroids or hyaluronidase are contraindicated, for those who cannot make frequent visit and to avoid pain due to injection.
Downloads
References
Schwartz J. Atrophia Idiopathica Mucosae Oris. In: Demonstrated at the 11th Int Dent Congress;1952.
Joshi SG. Fibrosis of the palate and pillars. Indian J Otolaryngol 1953;4(1).
Paymaster JC. Cancer of the buccal mucosa.A clinical study of 650 cases in Indian patients. Cancer 1956;9(3):431-435.
Pindborg JJ, Sirsat SM. Oral submucous fibrosis. Oral Surg. Oral Med. Oral Pathol. 1966;22(6):764-79.
Pindborg JJ, Mehta FS, Gupta PC, Daftary DK. Prevalence of oral submucous fibrosis among 50,915 Indian villagers. Br. J. Cancer 1968;22(4):646-54.
Pindborg JJ. Oral submucous fibrosis: A review. Ann. Acad. Med. Singapore 1989;18(5):603-607.
Murti PR, Bhonsle RB, Gupta PC, Daftary DK, Pindborg JJ, Mehta FS. Etiology of oral submucous fibrosis with special reference to the role of areca nut chewing. J. Oral Pathol. Med. 1995;24(4):145-52.
Murti PR, Bhonsle RB, Pindborg JJ, Daftary DK, Gupta PC, Mehta FS. Malignant transformation rate in oral submucous fibrosis over a 17-year period. Community Dent. Oral Epidemiol. 1985;13(6):340-1.
Tai YS, Liu BY, Wang JT, Sun A, Kwan HW, Chiang CP. Oral administration of milk from cows immunized with human intestinal bacteria leads to significant improvements of symptoms and signs in patients with oral submucous fibrosis. J. Oral Pathol. Med. 2001;30(10):618-25.
Krishnamoorthy B, Khan M. Management of oral submucous fibrosis by two different drug regimens: A comparative study. Dent. Res. J. (Isfahan). 2013;10(4):527-32.
Canniff JP, Harvey W, Harris M. Oral submucous fibrosis: its pathogenesis and management. Br. Dent. J. 1986;160(12):429-34.
Zhang M, Xu Y-J, Mengi SA, Arneja AS, Dhalla NS. Therapeutic potentials of pentoxifylline for treatment of cardiovascular diseases. Exp. Clin. Cardiol. 2004;9(2):103-11.
Ariyawardana A, Athukorala ADS, Arulanandam A. Effect of betel chewing, tobacco smoking and alcohol consumption on oral submucous fibrosis: a casecontrol study in Sri Lanka. J. Oral Pathol. Med. 2006;35(4):197-201.
Rajalalitha P, Vali S. Molecular pathogenesis of oral submucous fibrosis--a collagen metabolic disorder. J. Oral Pathol. Med. 2005;34(6):321-8.
N Dyavanagoudar S. Oral Submucous Fibrosis: Review on Etiopathogenesis. J. Cancer Sci. Ther. 2009;01(02):072-077.
Wanninayake Mudiyanselage Tilakaratne RPE. Oral Submucous Fibrosis: Review on Mechanisms of Pathogenesis and Malignant Transformation. J. Carcinog. Mutagen. 2013.
Yadav J. Role of Copper in Oral Submucous Fibrosis: A Cytological Correlation. Indian J. Dent. Sci. 2011;3(5):3-6.
Yang S-F, Hsieh Y-S, Tsai C-H, Chen Y-J, Chang Y-C. Increased plasminogen activator inhibitor-1/tissue type plasminogen activator ratio in oral submucous fibrosis. Oral Dis. 2007;13(2):234-8.
Tsai CC, Ma RH, Shieh TY. Deficiency in collagen and fibronectin phagocytosis by human buccal mucosa fibroblasts in vitro as a possible mechanism for oral submucous fibrosis. J. Oral Pathol. Med. 1999;28(2):59- 63.
Rajendran R, Paul S, Mathews PP, Raghul J, Mohanty M. Characterisation and quantification of mucosal vasculature in oral submucous fibrosis. Indian J. Dent. Res. 16(3):83-91.
Rajendran R, Sunil, Twinkle SP, Anikumar T V, Annie J. Cell death does not herald epithelial involution (“atrophy”) in oral sub mucous fibrosis: a TEM study. Indian J. Dent. Res. 15(1):13-9.
Thangjam GS, Agarwal P, Khan I, et al. Transglutaminase-2 regulation by arecoline in gingival fibroblasts. J. Dent. Res. 2009;88(2):170-5.
Tsai C-H, Yang S-F, Lee S-S, Chang Y-C. Augmented heme oxygenase-1 expression in areca quid chewing-associated oral submucous fibrosis. Oral Dis. 2009;15(4):281-6.
Chatuvedi VN, Sharma AK, Chakrabarati S. Salivary coagulopathy and humoral response in oral submucous fibrosis (OSMF). J. Indian Dent. Assoc. 1991;62(3):51-3, 59.
Gupta P, R Naik S, Nc S, Durgvanshi A, Agarwal N. Salivary IgA Levels in Patients with Oral Submucous Fibrosis: A Study. Kailasam S, ed. J. Indian Acad. Oral Med. Radiol. 2011;23(4):536-538.
Samlaska CP, Winfield EA. Pentoxifylline. J. Am. Acad. Dermatol. 1994;30(4):603-621.
Seidler NW, Swislocki NI. The effects of pentoxifylline on the plasma membrane Ca2+ ATPase in age-separated rat and human erythrocytes. J. Clin. Pharmacol. 1992;32(4):332-37.
Currie MS, Rao KM, Padmanabhan J, Jones A, Crawford J, Cohen HJ. Stimulus-specific effects of pentoxifylline on neutrophil CR3 expression, degranulation, and superoxide production. J. Leukoc. Biol. 1990;47(3):244-50.
Wakefield PE, James WD, Samlaska CP, Meltzer MS. Tumor necrosis factor. J. Am. Acad. Dermatol. 1991;24(5 Pt 1):675-85.
Berman B, Duncan MR. Pentoxifylline inhibits normal human dermal fibroblast in vitro proliferation, collagen, glycosaminoglycan, and fibronectin production, and increases collagenase activity. J. Invest. Dermatol. 1989;92(4):605-10.
Srinivasu P, Rao BR, Rao YM, Rambhau D. Biopharmaceutics: Drug Metabolism and Pharmacokinetics: Circadian Variations in the Pharmacokinetics of Pentoxifylline in Man. J. Pharm. Pharmacol. 1998;50(1):71-74.
Antignani PL, Todini AR, Saliceti F, Pacino G, Bartolo M. Results of clinical, laboratory and haemorheological investigations of the use of pentoxifylline in high doses. Pharmatherapeutica 1987;5(1):50-6.
Perego MA, Sergio G, Artale F, Giunti P, Danese C. Haemorrheological improvement by pentoxifylline in patients with peripheral arterial occlusive disease. Curr. Med. Res. Opin. 1986;10(2):135-8.
Aviado DM, Porter JM. Pentoxifylline: A New Drug for the Treatment of Intermittent Claudication; Mechanism of Action, Pharmacokinetics, Clinical Efficacy and Adverse Effects. Pharmacother. J. Hum. Pharmacol. Drug Ther. 1984;4(6):297-306.
Ellison MJ, Horner RD, Willis SE, Cummings DM. Influence of pentoxifylline on steady-state theophylline serum concentrations from sustained-release formulations. Pharmacotherapy 1990;10(6):383-6.
Dettori AG, Pini M, Moratti A, et al. Acenocoumarol and pentoxifylline in intermittent claudication. A controlled clinical study. The APIC Study Group. Angiology 1989;40(4 Pt 1):237-48.
Rajendran R, Vijayakumar T, Vasudevan DM. An alternative pathogenetic pathway for oral submucous fibrosis (OSMF). Med. Hypotheses 1989;30(1):35- 7.
Zabel P, Schade FU, Schlaak M. Inhibition of endogenous TNF formation by pentoxifylline. Immunobiology 1993;187(3-5):447-63.
Kreth S, Ledderose C, Luchting B, Weis F, Thiel M. Immunomodulatory properties of pentoxifylline are mediated via adenosine-dependent pathways. Shock 2010;34(1):10-6.
Shieh TY, Yang JF. Collagenase activity in oral submucous fibrosis. Proc. Natl. Sci. Counc. Repub. China. B. 1992;16(2):106-10.
Haque MF, Harris M, Meghji S, Barrett AW. Immunolocalization of cytokines and growth factors in oral submucous fibrosis. Cytokine 1998;10(9):713-9.
Rajendran R, Rani V, Shaikh S. Pentoxifylline therapy: a new adjunct in the treatment of oral submucous fibrosis. Indian J. Dent. Res. 17(4):190-8.
Published
How to Cite
Issue
Section
Copyright (c) 2021 International journal of health sciences
![Creative Commons License](http://i.creativecommons.org/l/by-nc-nd/4.0/88x31.png)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles published in the International Journal of Health Sciences (IJHS) are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJHS right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.
Articles published in IJHS can be copied, communicated and shared in their published form for non-commercial purposes provided full attribution is given to the author and the journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
This copyright notice applies to articles published in IJHS volumes 4 onwards. Please read about the copyright notices for previous volumes under Journal History.